Latest From Biotech Now

Jack the Ripper Mystery May Be Solved through DNA Testing

JacktheRipper1888

Author Russell Edwards and Jari Louhelainen, a molecular biology professor at Liverpool John Moores University claim to have solved the 126-year-old mystery surrounding the identity of Jack the Ripper, which is the pseudonym of a serial killer who murdered at least five women in East London in the late 1800s. Edwards bought a shawl that was found near the body of one of the victims – Catherine Eddowes – at an auction. He then worked Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Best Conspiracy Theories Never Die

8V608NWE

The best conspiracy theories never die. They evolve and adapt. They rebuff troublesome facts, plug their ears to common sense and embrace the outliers. There are no aliens at Area 51, Elvis has left the building, Obama was born in the USA – and Jenny McCarthy’s willfully ignorant anti-vaccine campaign has endangered lives. Diseases that were largely eradicated in the United States a generation ago—whooping cough, measles, mumps—are returning, in part because nervous parents are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Biotech Analyst Optimism: Price Targets Post-IPO

Stock Ticker

In a recent blog post, Bruce Booth of Life Sci VC, writes about the relationship between a forecasted price target of a biotech stock and its current share price. If biotech stocks hit their current targets, it could be a good year, Booth writes: “I’ll close with a thought experiment as an optimist: if, in line with historic data, 45% of the current IPO class hits their price targets at some point over the next Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Patients Suffering from Gaucher’s Disease Deserve Better

scientist-eyedropper

Gaucher Disease is one of the over 6,000 rare diseases that affect patients worldwide, representing a frontier of unmet medical need [NCATS, NIH]. The challenges for drug development generally—long and costly research and development timelines—are exacerbated by the inherently small patient populations affected by rare diseases. These patients can be difficult to identify and geographically dispersed and their clinical presentation can be quite disparate, complicating the design and recruitment for clinical trials used to determine Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Partnering in Latin America, According to the Experts

LatinAmerica_205x100_Thumbnail copy

Latin America is a hotbed for biotech activity. I recently sat down with four movers and shakers in Latin American biotech to get their thoughts and perspectives: Alexandre Boggio, Director, Business Development, Sanofi Pharma Brazil Carolina Tremmel, Director, New Business Development, Daiichi Sankyo Brasil Edurdo Tsuru, Director, Business Development Latin America, Mundipharma Thiago Mares Guia, MD, PhD, Medical and Scientific Manager, Bionovis See the interview on YouTube: Biotech in Latin America is growing: The Latin Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,